Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 242

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Beneficial Endocrine but Adverse Exocrine Effects of Sitagliptin in the Human Islet Amyloid Polypeptide Transgenic Rat Model of Type 2 Diabetes

Open access
Matveyenko, Aleksey V., Dry, Sarah, Cox, Heather I., Moshtaghian, Artemis, Gurlo, Tatyana, Galasso, Ryan, Butler, Alexandra E., Butler, Peter C.·2009·Diabetes

Abstract

OBJECTIVE: We sought to establish the extent and mechanisms by which sitagliptin and metformin singly and in combination modify islet disease progression in human islet amyloid polypeptide transgenic (HIP) rats, a model for type 2 diabetes. RESEARCH DESIGN AND METHODS: HIP rats were treated with sitagliptin, metformin, sitagliptin plus metformin, or no drug as controls for 12 weeks. Fasting blood glucose, insulin sensitivity, and β-cell mass, function, and turnover were measured in each group. RESULTS: Sitagliptin plus metformin had synergistic effects to preserve β-cell mass in HIP rats. Metformin more than sitagliptin inhibited β-cell apoptosis. Metformin enhanced hepatic insulin sensitivity; sitagliptin enhanced extrahepatic insulin sensitivity with a synergistic effect in combination. β-Cell function was partially preserved by sitagliptin plus metformin. However, sitagliptin treatment was associated with increased pancreatic ductal turnover, ductal metaplasia, and, in one rat, pancreatitis. CONCLUSIONS: The combination of metformin and sitagliptin had synergistic actions to preserve β-cell mass and function and enhance insulin sensitivity in the HIP rat model of type 2 diabetes. However, adverse actions of sitagliptin treatment on exocrine pancreas raise concerns that require further evaluation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/db09-0058

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 39

  1. King, 1998, Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections, Diabetes Care, 21, 1414, 10.2337/diacare.21.9.1414 · DOI · Paper page
  2. Xiang, 2006, Coordinate changes in plasma glucose and pancreatic beta-cell function in Latino women at high risk for type 2 diabetes, Diabetes, 55, 1074, 10.2337/diabetes.55.04.06.db05-1109 · DOI
  3. Butler, 2003, Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes, Diabetes, 52, 102, 10.2337/diabetes.52.1.102 · DOI · Paper page
  4. Huang, 2007, High expression rates of human islet amyloid polypeptide induce endoplasmic reticulum stress mediated beta-cell apoptosis, a characteristic of humans with type 2 but not type 1 diabetes, Diabetes, 56, 2016, 10.2337/db07-0197 · DOI · Paper page
  5. Laybutt, 2007, Endoplasmic reticulum stress contributes to beta cell apoptosis in type 2 diabetes, Diabetologia, 50, 752, 10.1007/s00125-006-0590-z · DOI · Paper page
  6. Matveyenko, 2006, Beta-cell deficit due to increased apoptosis in the human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes, Diabetes, 55, 2106, 10.2337/db05-1672 · DOI
  7. Butler, 2004, Diabetes due to a progressive defectin beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP rat): a new model for type 2 diabetes, Diabetes, 53, 1509, 10.2337/diabetes.53.6.1509 · DOI · Paper page
  8. Matveyenko, 2009, Successful versus failed adaptation to high-fat diet-induced insulin resistance: the role of IAPP-induced beta-cell endoplasmic reticulum stress, Diabetes, 58, 906, 10.2337/db08-1464 · DOI
  9. Xu, 1999, Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats, Diabetes, 48, 2270, 10.2337/diabetes.48.12.2270 · DOI · Paper page
  10. Buteau, 2001, Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation, Diabetes, 50, 2237, 10.2337/diabetes.50.10.2237 · DOI · Paper page
  11. Hui, 2003, Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway, Endocrinology, 144, 1444, 10.1210/en.2002-220897 · DOI · Paper page
  12. Deacon, 2002, Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective, Biochem Biophys Res Commun, 294, 1, 10.1016/S0006-291X(02)00359-5 · DOI
  13. Aschner, 2006, Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes, Diabetes Care, 29, 2632, 10.2337/dc06-0703 · DOI · Paper page
  14. Raz, 2006, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus, Diabetologia, 49, 2564, 10.1007/s00125-006-0416-z · DOI · Paper page
  15. Brazg, 2007, Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes, Diabetes Obes Metab, 9, 186, 10.1111/j.1463-1326.2006.00691.x · DOI
  16. Cure, 2008, Exenatide and rare adverse events, N Engl J Med, 358, 1969, 10.1056/NEJMc0707137 · DOI
  17. Matveyenko, 2008, Measurement of pulsatile insulin secretion in the rat: direct sampling from the hepatic portal vein, Am J Physiol Endocrinol Metab, 295, E569, 10.1152/ajpendo.90335.2008 · DOI
  18. Robertson, 2007, Estimation of beta-cell mass by metabolic tests: necessary, but how sufficient?, Diabetes, 56, 2420, 10.2337/db07-0742 · DOI
  19. Sakaguchi, 2006, Establishment of animal models for three types of pancreatitis and analyses of regeneration mechanisms, Pancreas, 33, 371, 10.1097/01.mpa.0000236734.39241.99 · DOI
  20. Emmrich, 1998, Immunohistochemical characterization of the pancreatic cellular infiltrate in normal pancreas, chronic pancreatitis and pancreatic carcinoma, Digestion, 59, 192, 10.1159/000007488 · DOI
  21. Kloppel, 2007, Chronic pancreatitis, pseudotumors and other tumor-like lesions, Mod Pathol, 20, S113, 10.1038/modpathol.3800690 · DOI · Paper page
  22. Willemer, 1989, Histochemical and ultrastructural characteristics of tubular complexes in human acute pancreatitis, Dig Dis Sci, 34, 46, 10.1007/BF01536153 · DOI
  23. Bockman, 1982, Origin of tubular complexes in human chronic pancreatitis, Am J Surg, 144, 243, 10.1016/0002-9610(82)90518-9 · DOI
  24. Parsa, 1985, Ductal metaplasia of human exocrine pancreas and its association with carcinoma, Cancer Res, 45, 1285
  25. Marchetti, 2004, Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin, J Clin Endocrinol Metab, 89, 5535, 10.1210/jc.2004-0150 · DOI · Paper page
  26. Rankin, 2009, Adaptive beta cell proliferation is severely restricted with advanced age, Diabetes, 10.2337/db08-1198 · DOI · Paper page
  27. Carpenter, 2005, Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery, N Engl J Med, 353, 2192, 10.1056/NEJM200511173532017 · DOI
  28. Hegen, 1997, Structure of CD26 (dipeptidyl peptidase IV) and function in human T cell activation, Adv Exp Med Biol, 421, 109, 10.1007/978-1-4757-9613-1_15 · DOI
  29. Wagner, 2001, A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease, Genes Dev, 15, 286, 10.1101/gad.184701 · DOI · Paper page
  30. Wagner, 2002, Transgenic overexpression of amphiregulin induces a mitogenic response selectively in pancreatic duct cells, Gastroenterology, 122, 1898, 10.1053/gast.2002.33594 · DOI
  31. Lowenfels, 1993, Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group, N Engl J Med, 328, 1433, 10.1056/NEJM199305203282001 · DOI · Paper page
  32. Eaden, 2001, The risk of colorectal cancer in ulcerative colitis: a meta-analysis, Gut, 48, 526, 10.1136/gut.48.4.526 · DOI · Paper page
  33. Meisterfeld, 2008, Pancreatic disorders and diabetes mellitus, Exp Clin Endocrinol Diabetes, 116, S7, 10.1055/s-2008-1080918 · DOI
  34. Everhart, 1995, Diabetes mellitus as a risk factor for pancreatic cancer: a meta-analysis, JAMA, 273, 1605, 10.1001/jama.1995.03520440059037 · DOI
  35. Michaud, 2007, Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women, Cancer Epidemiol Biomarkers Prev, 16, 2101, 10.1158/1055-9965.EPI-07-0182 · DOI
  36. Ishikawa, 1989, Morphologic characteristics of pancreatic carcinoma with diabetes mellitus, Cancer, 64, 1107, 10.1002/1097-0142(19890901)64:5<1107::AID-CNCR2820640523>3.0.CO;2-Y · doi:10.1002/1097-0142(19890901)64:5<1107::aid-cncr2820640523>3.0.co;2-y
  37. Cuzick, 1989, Pancreatic cancer, alcohol, diabetes mellitus and gall-bladder disease, Int J Cancer, 43, 415, 10.1002/ijc.2910430312 · DOI · Paper page
  38. Lankisch, 1982, Exocrine pancreatic function in insulin-dependent diabetes mellitus, Digestion, 25, 211, 10.1159/000198833 · DOI
  39. Bonner-Weir, 2004, The pancreatic ductal epithelium serves as a potential pool of progenitor cells, Pediatr Diabetes, 5, 16, 10.1111/j.1399-543X.2004.00075.x · DOI · Paper page

Cited by

See all 242

Metadata

Authors
Matveyenko, A. V., Dry, S., Cox, H. I., Moshtaghian, A., Gurlo, T., Galasso, R., Butler, A. E., & Butler, P. C.
Venue
Diabetes
Published
2009-04-29
Volume
58
Issue
7
Pages
1604-1615
ISSN
  • 0012-1797 (ISSN-L)
  • 1939-327X
OpenAlex
W2098008729
Cited by
242
References
19
FWCI
16.31
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.